RXi Pharmaceuticals Corp (NASDAQ:RXII)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $0.45, but opened at $0.44. RXi Pharmaceuticals shares last traded at $0.47, with a volume of 269354 shares changing hands.
RXII has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating on shares of RXi Pharmaceuticals in a research report on Monday, October 15th. ValuEngine upgraded RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
The stock has a market cap of $1.93 million, a P/E ratio of -0.10 and a beta of 2.07.
A hedge fund recently bought a new stake in RXi Pharmaceuticals stock. SG Americas Securities LLC purchased a new position in shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 118,387 shares of the biotechnology company’s stock, valued at approximately $228,000. SG Americas Securities LLC owned about 2.78% of RXi Pharmaceuticals at the end of the most recent reporting period. 8.87% of the stock is owned by hedge funds and other institutional investors.
About RXi Pharmaceuticals (NASDAQ:RXII)
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Read More: Discount Rate
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.